Abnehmspritzen: Stiftung Warentest hält nur zwei Wirkstoffe für geeignet
Stiftung Warentest evaluated several weight-loss injections and found only two active ingredients suitable. Semaglutid (Wegovy), administered weekly, can achieve a 9-12% weight loss that remains largely stable after two years.

Briefing Summary
AI-generatedStiftung Warentest evaluated several weight-loss injections and found only two active ingredients suitable. Semaglutid (Wegovy), administered weekly, can achieve a 9-12% weight loss that remains largely stable after two years. Both Semaglutid and another unnamed ingredient mimic hormones to induce satiety and slow digestion, but their long-term effects beyond 2-3 years are unknown, and weight regain is common after discontinuation. Liraglutid (Saxenda) only achieves a 4-5% weight loss after one year and has a higher rate of severe side effects and therapy discontinuation. Orlistat, a fat blocker, leads to only a 2-4% weight loss after two years and is also considered less suitable. The Stiftung Warentest highlights that both suitable medications deeply affect the metabolism.
Article analysis
Model · rule-basedKey claims
5 extractedLiraglutid (Saxenda) achieves only 4-5% weight loss after one year.
Both Semaglutid and another substance mimic the body's own hormones to signal satiety and slow gastric emptying.
Long-term effects of Semaglutid and another substance beyond two to three years are largely unknown.
Semaglutid (Wegovy) can achieve 9-12% weight loss after one year, which remains largely stable after two years.
Weight often increases again after discontinuing Semaglutid and another substance.